Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Roswell Park Cancer Institute
University of Illinois at Chicago
City of Hope Medical Center
City of Hope Medical Center
Shenzhen TargetRx, Inc.
University of Nebraska
M.D. Anderson Cancer Center
University of Nebraska
Nanfang Hospital, Southern Medical University
Fred Hutchinson Cancer Center
Jonsson Comprehensive Cancer Center
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
University of Maryland, Baltimore
Roswell Park Cancer Institute
University of Texas Southwestern Medical Center
University of Chicago
City of Hope Medical Center
Barbara Ann Karmanos Cancer Institute
Nohla Therapeutics, Inc.
City of Hope Medical Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gruppo Italiano Malattie EMatologiche dell'Adulto
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Children's Oncology Group
OHSU Knight Cancer Institute
Barbara Ann Karmanos Cancer Institute
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Memorial Sloan Kettering Cancer Center
The Korean Society of Blood and Marrow Transplantation
FDA Office of Orphan Products Development
Teva Branded Pharmaceutical Products R&D, Inc.
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
Mesoblast, Ltd.
City of Hope Medical Center
National Cancer Institute (NCI)